Publication Date:
2018
Description:
〈p〉Publication date: 7 March 2019〈/p〉
〈p〉〈b〉Source:〈/b〉 Journal of Colloid and Interface Science, Volume 538〈/p〉
〈p〉Author(s): Mengru Wang, Wanhua Liu, Yanqiu Zhang, Meng Dang, Yunlei Zhang, Jun Tao, Kun Chen, Xin Peng, Zhaogang Teng〈/p〉
〈div xml:lang="en"〉
〈h5〉Abstract〈/h5〉
〈div〉〈p〉The development of effective targeted therapies for triple negative breast cancer (TNBC) remains a challenge. This targeted drug delivery system used a near-infrared fluorescence dye cyanine 5.5 (Cy5.5) and an ICAM-1 antibody on thioether-bridged periodic mesoporous organosilica nanoparticles (PMOs). The ICAM-1 antibody and cyanine 5.5-engineered PMOs (PMO-Cy5.5-ICAM) offer excellent 〈em〉in vivo and in vitro〈/em〉 biocompatibility. The PMO-Cy5.5-ICAM shows a loading capacity up to 400 mg/g of doxorubicin (DOX). The drug release profile of the DOX-loaded targeted delivery system (DOX@PMO-Cy5.5-ICAM) is pH-sensitive. Confocal microscopy showed that the PMO-Cy5.5-ICAM efficiently targets and enters TNBC cells. In 〈em〉in vivo〈/em〉 experiments, the DOX@PMO-Cy5.5-ICAM accumulates more in TNBCs than in the control groups and exhibits better therapeutic effects on TNBC; thus, it is a promising treatment strategy for TNBC.〈/p〉〈/div〉
〈/div〉
〈div xml:lang="en"〉
〈h5〉Graphical abstract〈/h5〉
〈div〉
〈p〉Target therapy for TNBC with ICAM-1 antibody mediated mesoporous drug delivery system DOX@PMO-Cy5.5-ICAM.〈/p〉
〈p〉〈figure〉〈img src="https://ars.els-cdn.com/content/image/1-s2.0-S0021979718314668-ga1.jpg" width="274" alt="Graphical abstract for this article" title=""〉〈/figure〉〈/p〉
〈/div〉
〈/div〉
Print ISSN:
0021-9797
Electronic ISSN:
1095-7103
Topics:
Chemistry and Pharmacology
,
Physics
